Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared to placebo without any significant new adverse reactions, according to data from the POLESTAR study presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.